tem cell scientists scored what at first appeared an easy win for regenerative medicine when they discovered mesenchymal stem cells several decades ago. These cells, found in bone marrow, can give rise to fat, bone, and muscle tissue, and have been used in hundreds of clinical trials for tissue repair. Unfortunately, the results of these trials have been underwhelming. One problem is that these stem cells don’t stick around in the body long enough to benefit patients.
But Harvard Stem Cell Institute (HSCI) scientists at Boston Children’s Hospital aren’t ready to give up. A research team led by Juan Melero-Martin
The mesenchymal stem cells found in the bone marrow can give rise to bone, fat, and muscle tissue, and have been used in hundreds of clinical trials for tissue repair.
Unfortunately, the results of these trials have been underwhelming, the main problem being that these stem cells do not stick around in the body long enough to benefit the patient.
Researchers have now found that transplanting mesenchymal stem cells along with blood vessel-forming cells naturally found in circulation improves results.
Stem cells that could restore sight and hearing have been discovered in an experiment that has been performed successfully in animals. But according to two teams of scientists, it is an important step which will lead to future applications in humans.
A team from the Chonnam National University of South Korea was able to restore hearing in guinea pigs whose hearing was destroyed by chemical substances, using mesenchymal stem cells taken from human bone marrow. Other researchers at SUNY Upstate Medical University of Syracuse in the United States were able to restore sight in frogs using skin stem
With veterinarians across the country training to use stem cells for tendon and ligament repair, a professor at the University of California, Davis (UC Davis) wants to take the technology a step further by applying them to chronic, cell-based diseases.
Richard Vulliet, DVM, is very early into the work. But he is optimistic about the evidence as it exists, of course, and he may have had a success.
Vulliet has treated four dogs with degenerative myelopathy with their own stem cells, which he prefers to call mesenchymal stem cells or pluripotent marrow stromal cells. The terminology has evolved and those names
IntelliCell BioSciences filed its patent application with the US Patent office that will claim priority to its provisional US patent serial #61/427, 221 that was filed on December 27, 2010. The title of the patent application is Ultrasonic Cavitation Derived Stromal or Mesenchymal Vascular Extracts and Cells Derived Therefrom Obtained from Adipose Tissue and use Thereof. It covers the methods of manufacturing using ultrasonic cavitation to dissociate the fat cells and blood vessels contained within the adipose tissue, thereby obtaining multi-potent, mesenchymal or stromal vascular fractions for use in human subjects. These methods do not include the use of